ULISES' journey in the search for a new treatment in the fight against cancer came to an end last week. As a part of the ULISES Project’s legacy, the Consortium produced a set of factsheets to share some of the milestones achieved over the last 4 years, which include : 1) In vitro and in vivo validation of nanoparticle treatment to induce anti-tumour alloreactivity 2) Characterisation of a set of biological materials from PDAC patients Download the factsheet and dive in: https://lnkd.in/dBYeEi-P Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Victor Pallaruelo Santamaria Fundación Instituto Valenciano de Oncología (IVO) UMC Utrecht Leiden University Medical Center Instituto Murciano de Investigación Biosanitaria (IMIB) Universitat Politècnica de València (UPV) ICONS Innovation Strategies
ULISES PROJECT
Servicios de investigación
EU project that develops a treatment for cancer by making tumorous cells “visible” to the patient’s immune system.
Sobre nosotros
ULISES is a EU project that aims at developing an immunologic – based treatment strategy where cancer cells are “reprogrammed” to become “visible” to the patient’s own immune system. By using nanotechnologies to deliver plasmid DNA into tumorous cells for reprogramming, the ULISES project will develop a disruptive treatment that enables the immune system to see what has, until now, been invisible. This approach doesn't seek to alter genetics of the cancer cells; rather it helps the immune system to recognise and attack these cells once they've been "flagged" as incompatible. This breakthrough therapy developed by researchers in the ULISES project will offer several advantages over current therapies:much greater efficiency; use of the patient's own immune systemto attack the cancerous cells;and fewer side effects meaning improved patient outcomes. The ULISES project is funded under the H2020 FET-Open programme as part of the EIC Pathfinder pilot, promoting collaborative, inter-disciplinary research and innovation on science-inspired and radically new future technologies. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N° 899708.
- Sector
- Servicios de investigación
- Tamaño de la empresa
- De 11 a 50 empleados
- Sede
- Barcelona
- Tipo
- Organización sin ánimo de lucro
- Fundación
- 2020
Ubicaciones
-
Principal
Cómo llegar
Barcelona, ES
Empleados en ULISES PROJECT
Actualizaciones
-
🩺 According to the European Commission, cancer is on the rise in the EU, with the number of new cases reaching 2.7 million in 2022. #Cancer deaths for that same year also went up and were estimated to be at 1.3 million. Nanoparticles may be the future of the fight against #pancreatic cancer, but also tumours that currently have no cure options. Watch our video news release to discover the synthesis of the ULISES project milestones: https://lnkd.in/dfqBNbvd
-
-
🩺 In this interview, part of the series "Meet the Team", Victor Pallaruelo Santamaria, as author of the first ULISES technical project, explains his role in the project. Read more: https://lnkd.in/d_Vek8i9
-
-
🩺 Dr Jose Antonio Lopez-Guerrero from Fundación Instituto Valenciano de Oncología (IVO) at the Europe Biobank Week 2024, speaking about ISO20387, an international standard for technical competence on #biobanking that IVO is performing within the #ULISES project👇
-
-
🩺 Our partner Fundación Instituto Valenciano de Oncología (IVO)ía is attending Europe Biobank Week 2024: the congress will highlight state-of-the-art #biobanking innovations and research. Read more: https://lnkd.in/dGX5SB4M
-
-
🩺 In this interview, part of the series Meet the Team, Eric Spierings, Associate Professor and Medical Immunologist at the Universitair Medisch Centrum Utrecht, explains to us how his team is contributing to ULISES’ goals in fighting #cancer. Read more: https://lnkd.in/dKyzad2C
-
-
🩺 Today it's the international #WorldHealthDay! We celebrate it by reminding ourselves and our governments that we need to protect our right to #health as a basic human right. Know your health rights.
-
🩺 In this interview, part of the series Meet the Team, Dr. Sebastiaan Heidt explains the contribution of Leiden University Medical Center to the immunological part of ULISES PROJECT . Read more: https://lnkd.in/dnfti8Fp
-
-
🩺 In this interview, dr. Alfredo Minguela Puras, from the Instituto Murciano de Investigación Biosanitaria (IMIB), explains how his team is validating the ULISES PROJECT therapy developed by the consortium through in vitro and in vivo assays. Read more: https://lnkd.in/eTJv-wZd
-